Complete Genomics, a leading innovator in genomic sequencing, today announced a collaboration with SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, to launch and co-market MSK-ACCESS® and MSK-IMPACT® powered with SOPHiA DDM™ on Complete Genomics’ DNBSEQ-T1+ sequencing platform. The companies aim to broaden access to precision oncology testing by offering the best-in-class liquid biopsy and solid tumor applications to customers globally. The announcement was made from the Association for Molecular Pathology (AMP) Annual Meeting in Boston.
The collaboration integrates SOPHiA GENETICS’ advanced, AI-powered applications MSKIMPACT® and MSK-ACCESS® powered by SOPHiA DDM™, developed in collaboration with Memorial Sloan Kettering Cancer Center (MSK), with Complete Genomics’ newly launched DNBSEQ-T1+ sequencing platform. Together, Complete Genomics and SOPHiA GENETICS will provide an integrated, sample-to-report workflow for laboratories, marking a significant expansion of their partnership into the precision oncology research market.
“Pairing MSK-IMPACT® and MSK-ACCESS® powered with SOPHiA DDM™ with our DNBSEQ-T1+platform creates a powerful and accessible solution for laboratories looking to scale highquality cancer genomic profiling,” said Rob Tarbox, vice president of product and marketing at Complete Genomics. “By combining MSK’s rigorously validated assays, SOPHiA GENETICS’ robust analytics, and our sequencing technology, we are enabling decentralized labs to deliver faster, more accurate, and more affordable insights to clinicians and researchers.”
“This collaboration underscores SOPHiA GENETICS’ commitment to broadening access to data-driven medicine,” said Ross Muken, President, SOPHiA GENETICS. “Partnering with Complete Genomics to streamline use of MSK-IMPACT® and MSK-ACCESS® powered with SOPHiA DDM™ on the DNBSEQ-T1+ platform enables more laboratories around the world to adopt precision oncology through scalable, end-to-end genomic solutions.”
The DNBSEQ-T1+, powered by proprietary DNBSEQ technology, delivers Q40-level accuracy, optimized throughput from 500 million to 2 billion reads per flow cell. Each flow cell is able to be run independently, with a 24-hour paired-end 150bp run time, offering laboratories a costeffective and highly flexible sequencing solution. At maximum throughput, each T1+ flow cell can run up to 60 tumor-normal sample pairs for tissue, up to 16 tumor-normal sample pairs for liquid biopsy.
SOPHiA DDM™ is a technology-agnostic analytics platform that leverages AI to compute, standardize, and analyze healthcare data. Joint evaluation of MSK-IMPACT® and MSKACCESS® on the DNBSEQ-T1+ platform demonstrated highly concordant variant calls and allele frequencies compared with equivalent sequencing systems, while achieving lower background noise, reduced turnaround time, and seamless compatibility with existing SOPHiA DDM™ workflows.
This new offering provides clinical laboratories, cancer centers, and drug developers with a high-performance, cost-efficient path to implementing comprehensive genomic profiling for precision oncology research.
Also Read
